MESOBLAST Aktie

 

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

Mesoblast shares are in the spotlight after strong revenue growth from Ryoncil® boosted confidence in the company's outlook. The post Mesoblast earnings: surging cell therapy revenues highlight growth appeared first on The Motley Fool Australia....

This biotech could be high risk, high reward picks according to Bell Potter. The post Why Mesoblast shares could rise 40% in a year appeared first on The Motley Fool Australia....

These shares are having a good time on hump day. But why? The post Why DroneShield, James Hardie, Lifestyle Communities, and Mesoblast shares are storming higher appeared first on The Motley Fool Australia....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

These shares are having a better day than most on Tuesday. But why? The post Why DroneShield, Greatland Resources, Mesoblast, and Web Travel shares are storming higher today appeared first on The Motley Fool Australia....

Mesoblast (ASX:MSB) jumped around +8% in morning trades to $2.80 a pop…...

Investors are piling into Mesoblast shares today. But why? The post Why did the Mesoblast share price just rocket 13%? appeared first on The Motley Fool Australia....

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$21.9 million on Ryoncil® (remestemcel-L-rknd) sales for the quarter ended September 30, 2025. This represents a 66% increase on the prior quarter ended June 30, 2025, with similar gross to net adjustment....

Um den gesamten Artikel unter news.google.com zu lesen, klicken Sie bitte auf die Überschrift...

These shares are starting the week in the red. But why? The post Why DigiCo, Emerald Resources, Harvey Norman, and Mesoblast shares are dropping today appeared first on The Motley Fool Australia....

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthcare Common Procedure Coding System (HCPCS) J-Code assigned to Ryoncil® (remestemcel-L-rknd) by United States Medicare & Medicaid Services (CMS) became active for billing and reimbursement on October 1, 2025.1 Formal recognition by CMS is a significant milestone for Ryoncil® as the product becomes easier to bill and pay for....

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S. donors in the U.S. and designated as U.S. origin products not subject to tariffs on imported branded or patented pharmaceutical products....

Welcome to HotCopper's Director Trades column, where we take a look at all the…...

NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil® (remestemcel-L-rknd), the only mesenchymal stromal cell (MSC) product approved by the United States Food and Drug Administration (FDA), was highlighted this past week in presentations at the Morgan Stanley and Cantor Fitzgerald Annual Global Healthcare Conferences held in New York....

Um den gesamten Artikel unter seekingalpha.com zu lesen, klicken Sie bitte auf die Überschrift...

It's that time of day to check out which companies are trending…...

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast shareholders, Gregory George and William Gueck (“Investors”) to issue, at its sole discretion, up to US$50.0 million (A$76.8 million)1 of unsecured convertible notes. The funding is available at Mesoblast's option, following shareholder approval, to repay or reduce the amount owing to its secured lenders under the existing loan agreements and for general working capital purposes....

Let's see why Bell Potter is tipping this stock as a buy right now. The post Why Mesoblast shares could rocket 60% higher appeared first on The Motley Fool Australia....

These shares are ending the week in the red. But why? The post Why Lynas, Mesoblast, PEXA, and Sayona Mining shares are tumbling today appeared first on The Motley Fool Australia....